The following funding opportunities and announcements were released this week and may be of interest to your faculty. As a reminder, the strategic grants team in the AgriLife Research Office of Corporate Relations is available to coordinate large strategic grant proposals. Please don’t hesitate to call on us if a faculty member is considering such a proposal.
National Institute for Food and Agriculture (USDA-NIFA):
The purpose of the Crop Protection and Pest Management program is to address high priority issues related to pests and their management using IPM approaches at the state, regional and national levels. The CPPM program supports projects that will ensure food security and respond effectively to other major societal pest management challenges with comprehensive IPM approaches that are economically viable, ecologically prudent, and safe for human health. The CPPM program addresses IPM challenges for emerging issues and existing priority pest concerns that can be addressed more effectively with new and emerging technologies. The outcomes of the CPPM program are effective, affordable, and environmentally sound IPM practices and strategies needed to maintain agricultural productivity and healthy communities.
- Awards: May not exceed a total of $200,000 for applications with Project Directors (PD) from one state/U.S. territory. May not exceed a total of $325,000 for applications with Project Directors (PDs) from more than one state/U.S. territory. Project periods can range from 2 to 4 years.
- Full proposal due April 16, 2019
Department of Defense:
The FY19 Defense Appropriation provides $5 million (M) to the Department of Defense Tick-Borne Disease Research Program (TBDRP) to support innovative, high-impact tick-borne disease research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).
The TBDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 TBDRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
- Investigator-Initiated Research Award: $650,000 total (plus indirect costs) for 3 years
- Idea Award: $300,000 total (plus indirect costs) for 2 years
- Career Development Award: $250,000 total (plus indirect costs) for 3 years
- Program announcement to be released in April 2019
American Diabetes Association:
Pathway to Stop Diabetes (Limited Submission – must apply internally via the TAMU Limited Submission Program)
Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication. Pathway solicits nominations for candidates in all disciplines as applied to diabetes including medicine, biology, chemistry, computing, physics, mathematics and engineering. In addition, nomination of scientists from diverse backgrounds, including minority groups that are underrepresented in biomedical research, is strongly encouraged.
Institutions may nominate a maximum of one investigator per grant cycle. The nomination can be in one of the Pathway award types:
- Initiator Award for individuals in postdoctoral training.
- Accelerator Award for early-career diabetes researchers.
- Visionary Award for established investigators in other fields changing their focus to diabetes.
- TAMU Limited Submission Deadlines: Declare Intent by 4/3/19; Internal Proposal Due 4/10/19
- Sponsor Deadline: 7/1/19
National Institutes of Health (NIH):
The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies. This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants applying to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy.
Complex microbial-tumor interactions are best addressed with a team approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.
- Awards: Application budgets are not limited but need to reflect the actual needs of the proposed project. Project periods up to 5 years.
- Deadlines: Standard NIH R01 due dates apply – the first standard application due date for this FOA is June 5, 2019. Letters of intent must be received no more than 30 days before the application due date.
The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies.
This FOA will support basic, mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants responding to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy.
The FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy.
- Awards: $275,000 total (plus indirect costs) for up to 2 years.
- Deadlines: Standard NIH R21 due dates apply – the first standard application due date for this FOA is June 16, 2019. Letters of intent must be received no more than 30 days before the application due date.
The National Sea Grant College Program (Sea Grant) was enacted by U.S. Congress in 1966 (amended in 2008, Public Law 110-394) to support leveraged federal and state partnership that harness the intellectual capacity of the nation’s universities and research institutions to solve problems and generate opportunities in coastal communities. The National Sea Grant Office anticipates around $3,000,000 will be available to support research to address critical gaps in social, behavioral, and economic knowledge as it relates to U.S. aquaculture and the communities impacted and served by it. The initiative is informed by the National Strategic Plan for Federal Aquaculture Research; the Sea Grant 10-Year NOAA Sea Grant Aquaculture Vision; and previous research from federal, state, and university scientists. This document sets out requirements for submitting to NOAA-OAR-SG-2019-2005953. Additional guidance and tips on how best to prepare an application are provided in the Sea Grant General Application Guide available at (https://seagrant.noaa.gov/Portals/1/Guidance/SeaGrantGeneralApplicationGuide.pdf ).
- Awards: Up to $250,000 total
- Due May 1, 2019
As always, please feel free to contact me with any questions.
Julie B. Svetlik | Strategic Grant Coordinator
Texas A&M AgriLife Research
1500 Research Parkway | College Station, TX 77843-2583
O: 979-845-1260 | email@example.com